At Janssen, we are tirelessly pushing the boundaries of science to deliver transformational approaches for auto- and allo-antibody-mediated diseases, building on our legacy of leadership in immunology and understanding of immune pathway science. New insights are unlocking opportunities to help revolutionize maternal-fetal immunology, including a potential treatment for hemolytic disease of the fetus and newborn (HDFN) that is entering into a Phase 3 pivotal trial. Learn more about our work at the ISUOG World Congress 2023.